{
    "clinical_study": {
        "@rank": "90880", 
        "arm_group": [
            {
                "arm_group_label": "Arm A (HR and IR control)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT."
            }, 
            {
                "arm_group_label": "Arm B (HR and IR blinatumomab)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT."
            }, 
            {
                "arm_group_label": "Arm C (LR control)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance."
            }, 
            {
                "arm_group_label": "Arm D (LR blinatumomab)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive Block 2 over 4 weeks, Blinatumomab Block 2 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Block 3 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Block 3 over 5 weeks, and then Maintenance."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase III trial compares how well blinatumomab works compared with standard\n      combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that\n      has returned after a period of improvement (relapsed). Monoclonal antibodies, such as\n      blinatumomab, can block cancer growth by finding cancer cells and helping to kill them or\n      carrying cancer-killing substances to them. It is not yet known whether standard combination\n      chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute\n      lymphoblastic leukemia."
        }, 
        "brief_title": "Blinatumomab in Treating Younger Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia", 
        "condition": [
            "B-cell Adult Acute Lymphoblastic Leukemia", 
            "B-cell Childhood Acute Lymphoblastic Leukemia", 
            "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", 
            "Recurrent Adult Acute Lymphoblastic Leukemia", 
            "Recurrent Childhood Acute Lymphoblastic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Philadelphia Chromosome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To compare the 2-year disease free survival (DFS) of high risk (HR) and intermediate risk\n      (IR) relapse B-cell acute lymphoblastic leukemia (B-ALL) patients who are randomized\n      following induction block 1 chemotherapy to receive either two intensive chemotherapy blocks\n      or two 5-week blocks of blinatumomab (randomization R1).\n\n      II. To compare the 3-year DFS of low risk (LR) relapse B-ALL patients who are randomized\n      following block 2 chemotherapy to receive either chemotherapy alone or chemotherapy plus\n      blinatumomab (randomization R2).\n\n      SECONDARY OBJECTIVES:\n\n      I. To compare the rates of minimal residual disease (MRD) >= 0.01% at the end of block 2 and\n      block 3 for HR and IR relapse B-ALL patients in randomization R1.\n\n      II. To estimate, for treatment failure (TF) patients not previously receiving blinatumomab,\n      the hematologic complete remission rate (CR), rate of MRD < 0.01%, and proportion able to\n      proceed to hematopoietic stem cell transplant (HSCT) in CR after treatment with\n      blinatumomab.\n\n      III. To assess the feasibility and safety of rapid taper of immune suppression for the\n      subset of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no acute graft versus\n      host disease (aGVHD).\n\n      OUTLINE:\n\n      All patients receive Block 1 over 4 weeks.\n\n      BLOCK 1: Patients receive dexamethasone orally (PO) twice daily (BID) or intravenously (IV)\n      on days 1-5 and 15-19; vincristine sulfate IV over 1 minute on days 1, 8, 15, and 22;\n      pegaspargase IV over 1-2 hours on days 3 and 17; and mitoxantrone hydrochloride IV over\n      15-30 minutes on days 1-2. Patients with central nervous system (CNS) 1 or CNS2 also receive\n      methotrexate intrathecally (IT) on days 1 and 8. Patients with CNS3 or isolated CNS relapse\n      also receive methotrexate IT, hydrocortisone IT, and cytarabine IT on days 1, 8, 15, and 22.\n      High risk and intermediate risk patients are then assigned to randomization R1. Low risk\n      patients are assigned to randomization R2.\n\n      RANDOMIZATION R1 (HR and IR patients): Patients are randomized to 1 of 2 treatment arms.\n\n      ARM A: Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo\n      allogeneic HSCT.\n\n      ARM B: Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5\n      weeks, and then undergo allogeneic HSCT.\n\n      RANDOMIZATION R2 (LR patients): Patients are then randomized to 1 of 2 treatment arms.\n\n      ARM C: Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8\n      weeks, Continuation 2 over 8 weeks, and then Maintenance.\n\n      ARM D: Patients receive Block 2 over 4 weeks, Blinatumomab Block 2 over 5 weeks,\n      Continuation 1 over 8 weeks, Blinatumomab Block 3 over 5 weeks, Continuation 2 over 8 weeks,\n      Blinatumomab Block 3 over 5 weeks, and then Maintenance.\n\n      BLOCK 2: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine sulfate IV\n      over 1 minute on day 1; methotrexate IV over 36 hours on day 8; leucovorin calcium IV or PO\n      on days 9-10; pegaspargase IV over 1-2 hours on day 9; cyclophosphamide IV over 15-30\n      minutes on days 15-19; and etoposide IV over 1-2 hours on days 15-19. Patients with CNS1 or\n      CNS2 also receive methotrexate IT on day 8. Patients with CNS3 also receive methotrexate IT,\n      hydrocortisone IT, and cytarabine IT on days 8 and 22.\n\n      BLOCK 3: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine sulfate IV\n      over 1 minute on day 1; cytarabine IV over 3 hours every 12 hours on days 1, 2, 8, and 9;\n      asparaginase intramuscularly (IM) on days 2, 4, 9, 11, and 23; methotrexate IT on day 1 and\n      IV over 36 hours on day 22; leucovorin calcium PO or IV on days 23-24. Patients with CNS1 or\n      CNS2 also receive methotrexate IT on day 22. Patients with CNS3 also receive methotrexate\n      IT, hydrocortisone IT, and cytarabine IT on days 1 and 22.\n\n      BLINATUMOMAB BLOCK 1: Patients blinatumomab IV continuously on days 1-28 and dexamethasone\n      PO or IV on day 1. Patients with CNS1 or CNS2 also receive methotrexate IT on days 15 and\n      29. Patients with CNS3 also receive methotrexate IT, hydrocortisone IT, and cytarabine IT on\n      days 15 and 29.\n\n      BLINATUMOMAB BLOCK 2: Patients blinatumomab IV continuously on days 1-28 and dexamethasone\n      PO or IV on day 1. Patients with CNS1 or CNS2 also receive methotrexate IT on days 8 and 29.\n      Patients with CNS3 also receive methotrexate IT, hydrocortisone IT, and cytarabine IT on\n      days 8 and 29.\n\n      BLINATUMOMAB BLOCK 3: Patients blinatumomab IV continuously on days 1-28 and dexamethasone\n      PO or IV on day 1.\n\n      CONTINUATION 1 & 2: Patients receive dexamethasone PO BID or IV on days 1-5; vincristine\n      sulfate IV over 1 minute on day 1; mercaptopurine tablet PO on days 1-42; methotrexate PO on\n      days 8, 15, 29, and 36; leucovorin calcium PO or IV on days 23-24; cyclophosphamide IV over\n      15-30 minutes on days 42 and 49; etoposide IV over 1-2 hours on days 42 and 49; thioguanine\n      PO once daily on days 42-48; and cytarabine IV or subcutaneously (SC) on days 43-46 and\n      50-53. Patients with CNS1 or CNS2 also receive methotrexate IT on days 1 and 43. Patients\n      with CNS3 also receive methotrexate IT, hydrocortisone IT, and cytarabine IT on days 1 and\n      43; methotrexate PO every 6 hours on day 22; and methotrexate IV over 36 hours on day 22.\n\n      MAINTENANCE: Patients receive dexamethasone PO BID or IV on days 1-5, 29-33, and 57-61;\n      vincristine sulfate IV over 1 minute on days 1, 29, and 57; mercaptopurine tablet PO on days\n      1-84; and methotrexate PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Patients\n      with CNS1 or CNS2 also receive methotrexate IT on day 1. Patients with CNS3 also receive\n      methotrexate IT, hydrocortisone IT, and cytarabine IT on day 1. Courses repeat every 12\n      weeks for up to 2 years since the beginning of treatment in the absence of disease\n      progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up annually for 10 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  First relapse of B-ALL with or without extramedullary disease\n\n          -  No waiting period for patients who relapse while receiving standard maintenance\n             therapy\n\n          -  Patients who relapse on frontline therapy in phases other than maintenance must have\n             fully recovered from the acute toxic effects of all prior chemotherapy,\n             immunotherapy, or radiotherapy prior to entering this study\n\n          -  Cytotoxic therapy: at least 14 days since the completion of cytotoxic therapy with\n             the exception of hydroxyurea, which is permitted up to 24 hours prior to the start of\n             protocol therapy, or maintenance chemotherapy\n\n          -  Biologic (anti-neoplastic) agent: at least 7 days since the completion of therapy\n             with a biologic agent; for agents that have known adverse events occurring beyond 7\n             days after administration, this period must be extended beyond the time during which\n             adverse events are known to occur\n\n          -  Stem cell transplant or rescue: patients with prior stem cell transplant or rescue\n             are not eligible for this study\n\n          -  Patients must have a performance status corresponding to Eastern Cooperative Oncology\n             Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and\n             Lansky for patients =< 16 years of age\n\n          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70\n             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\n\n               -  1 to < 2 years: =< 0.6 mg/dL\n\n               -  2 to < 6 years: =< 0.8 mg/dL\n\n               -  6 to < 10 years: =< 1 mg/dL\n\n               -  10 to < 13 years: =< 1.2 mg/dL\n\n               -  Females >= 14 years: =< 1.4 mg/dL\n\n               -  Males 13 to < 16 years: =< 1.5 mg/dL\n\n               -  Males >= 16 years: =< 1.7 mg/dL\n\n          -  Direct bilirubin < 3.0 mg/dL\n\n          -  Shortening fraction of >= 27% by echocardiogram, or\n\n          -  Ejection fraction of >= 50% by radionuclide angiogram\n\n        Exclusion Criteria:\n\n          -  Philadelphia chromosome positive/breakpoint cluster region protein (BCR)-Abelson\n             murine leukemia viral oncogene homolog 1 (ABL1)+ ALL\n\n          -  Burkitt leukemia/lymphoma\n\n          -  T-lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (T-LL)\n\n          -  B-lymphoblastic lymphoma (B-LL)\n\n          -  Patients with known optic nerve and/or retinal involvement are not eligible; patients\n             who are presenting with visual disturbances should have an exam and, if indicated, a\n             magnetic resonance imaging (MRI) to determine optic nerve or retinal involvement\n\n          -  Patients with a known concomitant genetic syndrome, including Down syndrome, Bloom\n             syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman\n             syndrome or any other known bone marrow failure syndrome\n\n          -  Patients with known human immunodeficiency virus (HIV) infection\n\n          -  Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and\n             etoposide phosphate (Etopophos)\n\n          -  Patients who have had prior treatment with blinatumomab\n\n          -  Lactating females are not eligible unless they have agreed not to breastfeed their\n             infants\n\n          -  Female patients of childbearing potential are not eligible unless a negative\n             pregnancy test result has been obtained\n\n          -  Sexually active patients of reproductive potential who do not agree to use an\n             effective contraceptive method for the duration of their study participation\n\n          -  Patients with pre-existing significant central nervous system pathology that would\n             preclude treatment with blinatumomab, including: seizure disorder that has required\n             prolonged (at least 4 weeks) of continuous treatment with an antiepileptic drug\n             within the last year, history of cerebrovascular ischemia/hemorrhage, history of\n             severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis,\n             coordination /movement disorder, or autoimmune disease with CNS involvement\n\n          -  Pre-randomization R1 and R2: interval development of significant central nervous\n             system pathology that would preclude treatment with blinatumomab\n\n          -  Pre-hematopoietic stem cell transplant (HSCT): interval development of significant\n             pathology that would preclude HSCT including the following infectious and organ\n             system pathologies:\n\n               -  Infections: patients with HIV or uncontrolled fungal, bacterial or viral\n                  infections are excluded\n\n               -  Patients acquiring fungal disease during induction therapy may proceed if they\n                  have a significant response to antifungal therapy with no or minimal evidence of\n                  active disease remaining by computed tomography (CT) evaluation\n\n               -  Organ function requirements for HSCT: must meet the criteria for renal, biliary\n                  and cardiac function as outlined above; in addition, must have adequate\n                  pulmonary function defined as a forced expiratory volume in one second (FEV1),\n                  forced vital capacity (FVC), and diffusing capacity of the lung for carbon\n                  monoxide (DLCO) (corrected for hemoglobin [Hgb]) >= 60% by pulmonary function\n                  tests (PFTs)\n\n               -  For children who are unable to cooperate for PFTs, the criteria are: no evidence\n                  of dyspnea at rest, no exercise intolerance, and not requiring supplemental\n                  oxygen therapy\n\n          -  All patients and/or their parent or legal guardian must sign a written informed\n             consent\n\n          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute\n             (NCI) requirements for human studies must be met"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "438", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101853", 
            "org_study_id": "NCI-2014-00631", 
            "secondary_id": [
                "NCI-2014-00631", 
                "COG-AALL1331", 
                "AALL1331", 
                "AALL1331", 
                "U10CA098543", 
                "U10CA180886"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm B (HR and IR blinatumomab)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given PO or IV", 
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aeroseb-Dex", 
                    "Decaderm", 
                    "Decadron", 
                    "DM", 
                    "DXM"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "leurocristine sulfate", 
                    "VCR", 
                    "Vincasar PFS"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "pegaspargase", 
                "intervention_type": "Drug", 
                "other_name": [
                    "L-asparaginase with polyethylene glycol", 
                    "Oncaspar", 
                    "PEG-ASP", 
                    "PEG-L-asparaginase"
                ]
            }, 
            {
                "arm_group_label": "Arm A (HR and IR control)", 
                "description": "Given IV", 
                "intervention_name": "mitoxantrone hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CL 232315", 
                    "DHAD", 
                    "DHAQ", 
                    "Novantrone"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm B (HR and IR blinatumomab)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IT, IV, and PO", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "amethopterin", 
                    "Folex", 
                    "methylaminopterin", 
                    "Mexate", 
                    "MTX"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm B (HR and IR blinatumomab)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IT", 
                "intervention_name": "therapeutic hydrocortisone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aeroseb-HC", 
                    "Barseb HC", 
                    "Cetacort", 
                    "Cort-Dome", 
                    "Cortef"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm B (HR and IR blinatumomab)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IT and IV or SC", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IV or PO", 
                "intervention_name": "leucovorin calcium", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CF", 
                    "CFR", 
                    "LV"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CPM", 
                    "CTX", 
                    "Cytoxan", 
                    "Endoxan", 
                    "Endoxana"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "etoposide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "EPEG", 
                    "VP-16", 
                    "VP-16-213"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm C (LR control)"
                ], 
                "description": "Given IM", 
                "intervention_name": "asparaginase", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ASNase", 
                    "Colaspase", 
                    "Crasnitin", 
                    "Elspar", 
                    "L-ASP"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm B (HR and IR blinatumomab)"
                ], 
                "description": "Undergo allogeneic HSCT", 
                "intervention_name": "allogeneic hematopoietic stem cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Arm B (HR and IR blinatumomab)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "blinatumomab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103", 
                    "bispecific T-cell engager MT103", 
                    "MEDI-538", 
                    "MT-103"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given PO", 
                "intervention_name": "mercaptopurine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "6-mercaptopurine", 
                    "6-MP", 
                    "Leukerin", 
                    "MP"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Given PO", 
                "intervention_name": "thioguanine", 
                "intervention_type": "Drug", 
                "other_name": "6-TG"
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm B (HR and IR blinatumomab)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm A (HR and IR control)", 
                    "Arm B (HR and IR blinatumomab)", 
                    "Arm C (LR control)", 
                    "Arm D (LR blinatumomab)"
                ], 
                "description": "Optional correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "6-Mercaptopurine", 
                "Cytarabine", 
                "Methotrexate", 
                "Thioguanine", 
                "Cyclophosphamide", 
                "Pegaspargase", 
                "Asparaginase", 
                "Dexamethasone", 
                "Etoposide", 
                "Mitoxantrone", 
                "Vincristine", 
                "BB 1101", 
                "Antibodies, Monoclonal", 
                "Antibodies, Bispecific", 
                "Dexamethasone acetate", 
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Dexamethasone 21-phosphate", 
                "Hydrocortisone-17-butyrate", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "pbrown@jhmi.edu", 
                "last_name": "Patrick A. Brown", 
                "phone": "410-614-4915"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Children's Oncology Group"
            }, 
            "investigator": {
                "last_name": "Patrick A. Brown", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)", 
        "overall_official": {
            "affiliation": "Children's Oncology Group", 
            "last_name": "Patrick Brown", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "2-year DFS of HR and IR relapse patients", 
                "safety_issue": "No", 
                "time_frame": "From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assesses at 2 years"
            }, 
            {
                "measure": "3-year DFS of LR relapse patients", 
                "safety_issue": "No", 
                "time_frame": "From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last followup for those who are event-free, assessed at 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101853"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Will be compared at the end of Block 2 and 3 between randomized arms for HR and IR relapse patients.", 
                "measure": "Rates of MRD positivity (> 0.01%)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Morphologic CR rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Will be compared at the end of Block 2 and 3 between randomized arms for HR and IR relapse patients.", 
                "measure": "MRD negativity (< 0.01%) rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Proportion of patients that proceed to HSCT after treatment with blinatumomab (for treatment failure patients not previously receiving blinatumomab)", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "The observed rates of grade III-IV aGVHD among this subset will be calculated with 95% confidence intervals and compared descriptively to target rates.", 
                "measure": "Feasibility of rapid taper of immune suppression for subset of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no aGVHD defined as < 25% rate of grade III-IV aGVHD", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "The observed rates of TRM among this subset will be calculated with 95% confidence intervals and compared descriptively to target rates.", 
                "measure": "Safety of rapid taper of immune suppression for subset of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no aGVHD defined as < 5% rate of treatment-related mortality (TRM)", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}